Kiromic Biopharma, Inc. Shareholder News: Robbins LLP is Investigating Kiromic Biopharma, Inc. (KRBP) on Behalf of Shareholders

Author's Avatar
Aug 22, 2022

Shareholder rights law firm Robbins+LLP is investigating Kiromic Biopharma, Inc. (NASDAQ: KRBP) and its officers and directors to determine whether they breached fiduciary duties or violated securities laws in connection with the Company's July 2021 initial public offering ("IPO") by failing to disclose the FDA had placed a clinical hold on its two drug candidates. Kiromic presents itself as a target discovery and gene-editing company that utilizes artificial intelligence to create immunotherapy products.